PDB: 1820 resultsInfo pagesStatus searchChemie searchBIRD

---

7TEW	Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein in complex with human ACE2 (focused refinement of RBD and ACE2) Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose, Processed angiotensin-converting enzyme 2, Spike glycoprotein Authors: Zhu, X, Saville, J.W, Mannar, D, Srivastava, S.S, Berezuk, A.M, Demers, J.P, Zhou, S, Tuttle, K.S, Subramaniam, S. Deposit date: 2022-01-06 Release date: 2022-03-16 Method: ELECTRON MICROSCOPY (3.52 Å) Cite: Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nat Commun, 13, 2022
7TEZ	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein in complex with human ACE2 (focused refinement of RBD and ACE2) Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose, Processed angiotensin-converting enzyme 2, Spike glycoprotein Authors: Zhu, X, Saville, J.W, Mannar, D, Srivastava, S.S, Berezuk, A.M, Demers, J.P, Zhou, S, Tuttle, K.S, Subramaniam, S. Deposit date: 2022-01-06 Release date: 2022-03-16 Method: ELECTRON MICROSCOPY (3.27 Å) Cite: Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nat Commun, 13, 2022
7TF0	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein in complex with human ACE2 Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Processed angiotensin-converting enzyme 2, ... Authors: Zhu, X, Saville, J.W, Mannar, D, Srivastava, S.S, Berezuk, A.M, Demers, J.P, Zhou, S, Tuttle, K.S, Subramaniam, S. Deposit date: 2022-01-06 Release date: 2022-03-30 Method: ELECTRON MICROSCOPY (3.02 Å) Cite: Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nat Commun, 13, 2022
7TF5	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein Authors: Zhu, X, Saville, J.W, Mannar, D, Srivastava, S.S, Berezuk, A.M, Demers, J.P, Zhou, S, Tuttle, K.S, Subramaniam, S. Deposit date: 2022-01-06 Release date: 2022-03-30 Method: ELECTRON MICROSCOPY (3.16 Å) Cite: Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nat Commun, 13, 2022
7TF2	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) Q484I spike protein Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein Authors: Zhu, X, Saville, J.W, Mannar, D, Srivastava, S.S, Berezuk, A.M, Demers, J.P, Zhou, S, Tuttle, K.S, Subramaniam, S. Deposit date: 2022-01-06 Release date: 2022-03-30 Method: ELECTRON MICROSCOPY (3.62 Å) Cite: Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nat Commun, 13, 2022
7TEX	Cryo-EM structure of SARS-CoV-2 Delta (B.1.617.2) spike protein in complex with human ACE2 Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Processed angiotensin-converting enzyme 2, ... Authors: Zhu, X, Saville, J.W, Mannar, D, Srivastava, S.S, Berezuk, A.M, Demers, J.P, Zhou, S, Tuttle, K.S, Subramaniam, S. Deposit date: 2022-01-06 Release date: 2022-03-30 Method: ELECTRON MICROSCOPY (3.27 Å) Cite: Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nat Commun, 13, 2022
7TF4	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) spike protein (focused refinement of RBD) Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein Authors: Zhu, X, Saville, J.W, Mannar, D, Srivastava, S.S, Berezuk, A.M, Demers, J.P, Zhou, S, Tuttle, K.S, Subramaniam, S. Deposit date: 2022-01-06 Release date: 2022-03-30 Method: ELECTRON MICROSCOPY (3.01 Å) Cite: Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nat Commun, 13, 2022
7TF3	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) Q484A spike protein Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein Authors: Zhu, X, Saville, J.W, Mannar, D, Srivastava, S.S, Berezuk, A.M, Demers, J.P, Zhou, S, Tuttle, K.S, Subramaniam, S. Deposit date: 2022-01-06 Release date: 2022-03-30 Method: ELECTRON MICROSCOPY (2.25 Å) Cite: Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nat Commun, 13, 2022
7TF1	Cryo-EM structure of SARS-CoV-2 Kappa (B.1.617.1) Q484I spike protein (focused refinement of RBD) Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein Authors: Zhu, X, Saville, J.W, Mannar, D, Srivastava, S.S, Berezuk, A.M, Demers, J.P, Zhou, S, Tuttle, K.S, Subramaniam, S. Deposit date: 2022-01-06 Release date: 2022-03-30 Method: ELECTRON MICROSCOPY (3.57 Å) Cite: Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. Nat Commun, 13, 2022
7TA7	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 10/11 Descriptor: 3C-like proteinase, GLYCEROL, Nonstructural protein 10/11 Authors: Shaqra, A.M, Schiffer, C.A. Deposit date: 2021-12-20 Release date: 2022-06-22 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (2.28 Å) Cite: Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat Commun, 13, 2022
7TQ4	Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 6c Descriptor: 3C-like proteinase, N~2~-({[(1R,2R)-2-(3-chlorophenyl)cyclopropyl]methoxy}carbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-leucinamide Authors: Lovell, S, Battaile, K.P, Nguyen, H.N, Chamandi, S.D, Picard, H.R, Madden, T.K, Thruman, H.A, Kim, Y, Groutas, W.C, Chang, K.O. Deposit date: 2022-01-26 Release date: 2022-06-22 Last modified: 2023-10-25 Method: X-RAY DIFFRACTION (2.45 Å) Cite: Broad-Spectrum Cyclopropane-Based Inhibitors of Coronavirus 3C-like Proteases: Biochemical, Structural, and Virological Studies. Acs Pharmacol Transl Sci, 6, 2023
7T9Y	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 8/9 Descriptor: 3C-like proteinase, GLYCEROL, Nonstructural protein 8/9 Authors: Shaqra, A.M, Schiffer, C.A. Deposit date: 2021-12-20 Release date: 2022-06-22 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (2.18 Å) Cite: Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat Commun, 13, 2022
7T8R	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 7/8 Descriptor: 1,2-ETHANEDIOL, 3C-like proteinase, GLYCEROL, ... Authors: Shaqra, A.M, Schiffer, C.A. Deposit date: 2021-12-16 Release date: 2022-06-22 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (1.74 Å) Cite: Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat Commun, 13, 2022
7TQ2	Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 1c Descriptor: 3C-like proteinase, N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-N~2~-({[(1R,2R)-2-phenylcyclopropyl]methoxy}carbonyl)-L-leucinamide Authors: Lovell, S, Kashipathy, M.M, Battaile, K.P, Nguyen, H.N, Chamandi, S.D, Picard, H.R, Madden, T.K, Thruman, H.A, Kim, Y, Groutas, W.C, Chang, K.O. Deposit date: 2022-01-26 Release date: 2022-06-22 Last modified: 2023-10-25 Method: X-RAY DIFFRACTION (2.3 Å) Cite: Broad-Spectrum Cyclopropane-Based Inhibitors of Coronavirus 3C-like Proteases: Biochemical, Structural, and Virological Studies. Acs Pharmacol Transl Sci, 6, 2023
7TC4	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 15/16 Descriptor: 3C-like proteinase, GLYCEROL, Nonstructural protein 15/16 Authors: Shaqra, A.M, Schiffer, C.A. Deposit date: 2021-12-22 Release date: 2022-06-22 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (1.94 Å) Cite: Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat Commun, 13, 2022
7TQ3	Structure of SARS-CoV-2 3CL protease in complex with the cyclopropane based inhibitor 5c Descriptor: 3C-like proteinase, N~2~-({[(1R,2R)-2-(3-fluorophenyl)cyclopropyl]methoxy}carbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-leucinamide Authors: Lovell, S, Battaile, K.P, Nguyen, H.N, Chamandi, S.D, Picard, H.R, Madden, T.K, Thruman, H.A, Kim, Y, Groutas, W.C, Chang, K.O. Deposit date: 2022-01-26 Release date: 2022-06-22 Last modified: 2023-10-25 Method: X-RAY DIFFRACTION (2 Å) Cite: Broad-Spectrum Cyclopropane-Based Inhibitors of Coronavirus 3C-like Proteases: Biochemical, Structural, and Virological Studies. Acs Pharmacol Transl Sci, 6, 2023
7TB2	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 12/13 Descriptor: 3C-like proteinase, Nonstructural protein 12/13 Authors: Shaqra, A.M, Schiffer, C.A. Deposit date: 2021-12-21 Release date: 2022-06-22 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (1.8 Å) Cite: Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat Commun, 13, 2022
7T8M	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 5/6 Descriptor: 3C-like proteinase, DIMETHYL SULFOXIDE, GLYCEROL, ... Authors: Shaqra, A.M, Schiffer, C.A. Deposit date: 2021-12-16 Release date: 2022-06-22 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (1.6 Å) Cite: Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat Commun, 13, 2022
7T70	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 4/5 Descriptor: 3C-like proteinase, DIMETHYL SULFOXIDE, GLYCEROL, ... Authors: Shaqra, A.M, Schiffer, C.A. Deposit date: 2021-12-14 Release date: 2022-06-22 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (2.35 Å) Cite: Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat Commun, 13, 2022
7TA4	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 9/10 Descriptor: 3C-like proteinase, Nonstructural protein 9/10 Authors: Shaqra, A.M, Schiffer, C.A. Deposit date: 2021-12-20 Release date: 2022-06-22 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (1.78 Å) Cite: Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat Commun, 13, 2022
7TBT	Co-crystal structure of SARS-CoV-2 Mpro C145A with substrate peptide 13/14 Descriptor: 3C-like proteinase, Nonstructural protein 13/14 Authors: Shaqra, A.M, Schiffer, C.A. Deposit date: 2021-12-22 Release date: 2022-06-22 Last modified: 2023-10-18 Method: X-RAY DIFFRACTION (2.45 Å) Cite: Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Nat Commun, 13, 2022
7TEK	SARS-CoV-2 3CLPro in complex with N-(4-(1H-pyrazol-4-yl)phenyl)-N-(3-chlorobenzyl)-2-(pyridin-3-yl)acetamide Descriptor: 3C-like proteinase, N-[(3-chlorophenyl)methyl]-N-[4-(1H-pyrazol-4-yl)phenyl]-2-(pyridin-3-yl)acetamide Authors: Goins, C.M, Stauffer, S.R. Deposit date: 2022-01-05 Release date: 2023-01-11 Last modified: 2023-10-25 Method: X-RAY DIFFRACTION (2.2 Å) Cite: SARS-CoV-2 3CL-protease inhibitors derived from ML300: investigation of P1 and replacements of the 1,2,3-benzotriazole Med.Chem.Res., 2023
7TEL	SARS-CoV-2 3CLPro in complex with N-(4-(1H-imidazol-4-yl)phenyl)-N-(3-chloro-5-fluorobenzyl)-2-(isoquinolin-4-yl)acetamide Descriptor: 3C-like proteinase, N-[(3-chloro-5-fluorophenyl)methyl]-N-[4-(1H-imidazol-4-yl)phenyl]-2-(isoquinolin-4-yl)acetamide Authors: Goins, C.M, Stauffer, S.R. Deposit date: 2022-01-05 Release date: 2023-01-11 Last modified: 2023-10-25 Method: X-RAY DIFFRACTION (2.4 Å) Cite: SARS-CoV-2 3CL-protease inhibitors derived from ML300: investigation of P1 and replacements of the 1,2,3-benzotriazole Med.Chem.Res., 2023
7UHC	SARS-CoV-2 spike in complex with AHB2-2GS-SB175 Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Multivalent miniprotein inhibitor AHB2-2GS-SB175, ... Authors: Park, Y.J, Seattle Structural Genomics Center for Infectious Disease (SSGCID), Veesler, D. Deposit date: 2022-03-26 Release date: 2022-06-08 Method: ELECTRON MICROSCOPY (3.1 Å) Cite: Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. Sci Transl Med, 14, 2022
7UHB	SARS-CoV-2 spike in complex with AHB2-2GS-SB175 (local refinement of the RBD and AHB2) Descriptor: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, Multivalent miniprotein inhibitor AHB2-2GS-SB175, Spike glycoprotein Authors: Park, Y.J, Seattle Structural Genomics Center for Infectious Disease (SSGCID), Veesler, D. Deposit date: 2022-03-26 Release date: 2022-06-08 Method: ELECTRON MICROSCOPY (3 Å) Cite: Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. Sci Transl Med, 14, 2022

<891011121314151617181920212223>